-
Tytuł:
-
Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1).
-
Autorzy:
-
Naito, Yoichi
Aburatani, Hiroyuki
Amano, Toraji
Baba, Eishi
Furukawa, Toru
Hayashida, Tetsu
Hiyama, Eiso
Ikeda, Sadakatsu
Kanai, Masashi
Kato, Motohiro
Kinoshita, Ichiro
Kiyota, Naomi
Kohno, Takashi
Kohsaka, Shinji
Komine, Keigo
Matsumura, Itaru
Miura, Yuji
Nakamura, Yoshiaki
Natsume, Atsushi
Nishio, Kazuto
-
Temat:
-
NUCLEOTIDE sequencing
MEDICAL personnel
CANCER diagnosis
CANCER treatment
MEDICAL societies
-
Źródło:
-
International Journal of Clinical Oncology; 2021, Vol. 26 Issue 2, p233-283, 51p
-
Background: To promote precision oncology in clinical practice, the Japanese Society of Medical Oncology, the Japanese Society of Clinical Oncology, and the Japanese Cancer Association, jointly published "Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment" in 2017. Since new information on cancer genomic medicine has emerged since the 1st edition of the guidance was released, including reimbursement for NGS-based multiplex gene panel tests in 2019, the guidance revision was made. Methods: A working group was organized with 33 researchers from cancer genomic medicine designated core hospitals and other academic institutions. For an impartial evaluation of the draft version, eight committee members from each society conducted an external evaluation. Public comments were also made on the draft. The finalized Japanese version was published on the websites of the three societies in March 2020. Results: The revised edition consists of two parts: an explanation of the cancer genomic profiling test (General Discussion) and clinical questions (CQs) that are of concern in clinical practice. Particularly, patient selection should be based on the expectation that the patient's post-test general condition and organ function will be able to tolerate drug therapy, and the optimal timing of test should be considered in consideration of subsequent treatment plans, not limited to treatment lines. Conclusion: We expect that the revised version will be used by healthcare professionals and will also need to be continually reviewed in line with future developments in cancer genome medicine. [ABSTRACT FROM AUTHOR]
Copyright of International Journal of Clinical Oncology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)